ALK and non-small cell lung carcinoma: Two randomized studies have shown that alectinib compared to crizotinib elicited increased overall response rates and PFS in patients with previously untreated ALK-mutated NSCLC, thus indicating that Alectinib could represent a first-line treatment option [335,336].